Eli Lilly Challenges Whistleblower Law at Supreme Court

Drugmaker argues False Claims Act's qui tam provisions let 'private bounty hunters' overstep constitutional bounds.

Mar. 28, 2026 at 5:07pm

Got story updates? Submit your updates here. ›

Indianapolis-based pharmaceutical company Eli Lilly has asked the U.S. Supreme Court to narrow the False Claims Act's powerful whistleblower provisions, arguing that the Civil War-era law has turned private citizens into unaccountable enforcers of federal fraud cases. Lilly's challenge stems from a $183 million judgment against the company over how it reported drug prices to Medicaid, a case brought by whistleblower Ronald Streck under the False Claims Act's qui tam setup.

Why it matters

Lilly's constitutional arguments and fee-shifting challenge could dramatically reset incentives for whistleblowers and affect how aggressively federal and state governments try to claw back money they say was obtained through fraud. The Justice Department has reported that False Claims Act cases brought in fiscal 2025 returned a record $6.8 billion in settlements and judgments to taxpayers, with qui tam suits supplying a major piece of that total recovery.

The details

In its Supreme Court filings, Lilly argues that the False Claims Act's qui tam setup lets profit-driven private relators press federal enforcement actions without the kind of presidential oversight the Constitution envisions. The company is also taking aim at a fee-shifting rule that can stick defendants with a relator's legal bills, even when the government has not taken over the case. The case that brought Lilly to this point began in 2014 when relator Ronald Streck sued under the False Claims Act, alleging that Lilly misreported its Average Manufacturer Price for Medicaid rebate purposes. A federal jury sided with Streck in 2022, awarding roughly $61 million in damages, which was then trebled to about $183 million under the False Claims Act.

  • In 2014, relator Ronald Streck sued Eli Lilly under the False Claims Act.
  • In August 2022, a federal jury awarded Streck roughly $61 million in damages against Lilly.
  • The $61 million jury award was then trebled to about $183 million under the False Claims Act's trebling provision.
  • The Seventh Circuit later upheld core findings on falsity, materiality and scienter in the case against Lilly.
  • In March 2026, Eli Lilly's deadline to file a certiorari petition with the U.S. Supreme Court was extended to March 21, 2026.

The players

Eli Lilly

An Indianapolis-based pharmaceutical company that is challenging the False Claims Act's whistleblower provisions at the U.S. Supreme Court.

Ronald Streck

A relator who sued Eli Lilly under the False Claims Act, alleging the company misreported its Average Manufacturer Price for Medicaid rebate purposes.

U.S. Supreme Court

The highest court in the United States that will hear Eli Lilly's challenge to the False Claims Act's qui tam provisions.

U.S. Department of Justice

The federal agency that has reported a record $6.8 billion in False Claims Act settlements and judgments in fiscal 2025, with qui tam suits supplying a major piece of that total recovery.

Washington Legal Foundation

A business and advocacy group that has urged courts to narrow the False Claims Act, arguing the qui tam structure invites overreaching private prosecutions and creates regulatory uncertainty for companies.

Got photos? Submit your photos here. ›

What they’re saying

“Private bounty hunters, accountable to no one but themselves, [may] enforce federal law on behalf of and in the name of the United States.”

— Eli Lilly

“The jury's decision sent money back to Medicaid and showed exactly why relators matter in policing fraud against public programs.”

— Ronald Streck's legal team

What’s next

The Supreme Court will decide whether to hear Eli Lilly's challenge to the False Claims Act's qui tam provisions. If the court agrees to take up the case, its ruling could reshape how whistleblower suits move forward and how state and federal governments recover money they claim was lost to fraud.

The takeaway

Eli Lilly's challenge to the False Claims Act's whistleblower provisions highlights the ongoing debate over the balance between empowering private citizens to expose fraud and maintaining proper government oversight. The Supreme Court's decision on this case could have far-reaching implications for how aggressively the government pursues fraud recovery efforts.